Acalabrutinib wins US FDA approval for mantle cell lymphoma treatment

Report on AstraZeneca blood cancer drug Calquence or acalabrutinib FDA approval for mantle cell lymphoma treatment in adult patients who had at least one prior therapy.

Acalabrutinib wins US FDA approval for mantle cell lymphoma treatment

Acalabrutinib FDA approval : AstraZeneca has secured an early approval for its blood cancer drug Calquence (acalabrutinib) for the treatment of mantle cell lymphoma in adult patients who were subjected to a minimum of one prior therapy for the rare type of blood cancer. According to the National Cancer Institute at the National Institutes of […]

AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation

AstraZeneca lung cancer drug Tagrisso (osimertinib) for the treatment of non-small cell lung cancer (NSCLC) in a first line setting has been granted the breakthrough therapy designation by the by the US Food and Drug Administration.

AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation

Pharma news updates : Tagrisso (osimertinib), the AstraZeneca lung cancer drug has bagged the breakthrough therapy designation (BTD) from the US FDA for the treatment of non-small cell lung cancer (NSCLC) in a first line setting. The BTD designation for the AstraZeneca cancer drug is specifically for treating metastatic NSCLC patients who have tested positive […]

Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances

Check out details of Astrazeneca Ovarian Cancer Drug, Lynparza which in a phase 3 trial has been demonstrated to have improved survival of patients treated with Lynparza Ovarian Cancer Tablets.

Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances

Pharma giant AstraZeneca has reported that its ovarian cancer drug Lynparza (olaparib) as a maintenance therapy has considerably improved the survival chances of patients with germline BRCA-mutations (gBRCA) who had a relapse of the disease, who did not respond to platinum-based chemo. Phase 3 Trial of Astrazeneca Ovarian Cancer Drug Lynparza The observation of the […]

AstraZeneca, Sanofi form R&D alliance for infant respiratory drug

AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals.

AstraZeneca, Sanofi form R&D alliance for infant respiratory drug

AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals. While MedImmune is the global biotech arm of British-Swedish pharma giant, Sanofi Pasteur is the vaccines division of French […]